A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
Phase 1/2
Terminated
NCT05159388
| Condition | Solid Tumor |
|---|
| Phase | Phase 1/2 |
|---|
| Sponsor | Servier Bio-Innovation LLC |
|---|
| Status | Terminated |
|---|
| Enrollment | 46 participants |
|---|
| Interventions | PRS-344/S095012 |
|---|
| Start date | Sep 8, 2021 |
|---|
| Completion date | Apr 1, 2025 |
|---|
| Results posted | Jun 16, 2026 |
|---|
Summary
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
Safety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment
28 days · Participants
| PRS-344/S095012 12mg | 0 Participants |
|---|
| PRS-344/S095012 36mg | 1 Participants |
|---|
| PRS-344/S095012 60mg | 3 Participants |
|---|
| PRS-344/S095012 80mg | 1 Participants |
|---|
| PRS-344/S095012 36mg and Obinutuzumab | 3 Participants |
|---|
Safety Measurements: Number of Participants With at Least One AE
Through study termination, approximately 3.5 years · Participants
| PRS-344/S095012 12mg | 4 Participants |
|---|
| PRS-344/S095012 36mg | 9 Participants |
|---|
| PRS-344/S095012 60mg | 14 Participants |
|---|
| PRS-344/S095012 80mg | 6 Participants |
|---|
| PRS-344/S095012 36mg and Obinutuzumab | 12 Participants |
|---|
Safety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation
Through study termination, approximately 3.5 years · Participants
| PRS-344/S095012 12mg | 1 Participants |
|---|
| PRS-344/S095012 36mg | 4 Participants |
|---|
| PRS-344/S095012 60mg | 7 Participants |
|---|
| PRS-344/S095012 80mg | 2 Participants |
|---|
| PRS-344/S095012 36mg and Obinutuzumab | 7 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.